On December 10, 2025, Onconetix, Inc. (ONCO) disclosed an amendment to a key partnership agreement through an SEC 8-K filing. The filing revealed that the company's subsidiary, Proteomedix AG, amended its license agreement with Labcorp to include the PRIME Study for Proclarix, a prostate cancer risk identification test, with milestone-based payments totaling up to $300,000.

The amendment, effective December 6, 2025, modifies the original license agreement dated March 27, 2023, according to the filing. The PRIME Study (Prostate Cancer Risk Identification in a Multi-Ethnic Cohort) is described as a prospective U.S.-based multi-center validation study of Proclarix. The amendment specifies that Labcorp will not pay royalties for the risk calculator used in the PRIME Study, while maintaining milestone-based payments up to the $300,000 aggregate maximum.

Three executives signed the amendment, according to Exhibit 10.1 attached to the filing. Proteomedix AG CEO Beat Rheiner, PhD and Chairman Thomas Meier, PhD represented the Onconetix subsidiary, while Labcorp CSO and Senior Vice President Marcia T. Eisenberg, PhD signed for the diagnostic testing company. The filing included the PRIME Study protocol as Exhibit C, detailing the study design and objectives.